US Tumor Marker Testing Market

Nov 03, 2011, 10:26 ET from Reportlinker

NEW YORK, Nov. 3, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

US Tumor Marker Testing Market

http://www.reportlinker.com/p0591360/US-Tumor-Marker-Testing-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

Highlights

  • Comprehensive 620-page analysis of the US tumor marker testing market.
  • Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years.
  • Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.
  • Ten-year test volume and sales forecasts over for 40 tumor marker performed in US hospitals, commercial laboratories and physician offices.
  • Placements and installed base of automated and semi-automated analyzers used for tumor marker testing.
  • Current instrumentation technologies and feature comparison of leading analyzers.
  • Sales and market shares of leading suppliers.
  • Emerging diagnostic technologies and their potential market applications.
  • Product development opportunities.
  • Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.
  • Business opportunities and strategic recommendations for suppliers.

Contains 620 pages and 103 tables

Table of Contents

Introduction

Worldwide Market and Technology Overview

A. Cancer Statistics and Etiology

1. Bladder

2. Breast

3. Cervical

4. Colon and Rectum

5. Endometrial

6. Esophagus

7. Head and Neck

8. Leukemia

9. Lung

10. Lymphoma

11. Oral

12. Ovarian

13. Prostate

14. Renal Cell Carcinoma

15. Skin

16. Stomach

17. Uterine

B. Major Current And Emerging Tumor Marker

1. Introduction

2. Tumor Marker Classification

3. ACTH

4. AlphaFetoprotein (AFP)

5. Beta2 Microglobulin

6. CA 153/27.29

7. CA 199

8. CA125

9. Calcitonin

10. Carcinoembrionic Antigen (CEA)

11. Estrogen and Progesterone Receptors

12. Ferritin

13. Gastrin

14. Human Chorionic Gonadotropin (HCG)

15. Insulin

16. Lymphocytes CD4/CD8

17. NSE

18. Occult Blood

19. PAP Smear/HPV

20. Prostatic Acid Phosphatase (PAP)

21. ProstateSpecific Antigen (PSA)

22. Squamous Cell Carcinoma Antigen (SCC)

23. TdT

24. Thyroglobulin

25. Tissue Polypeptide Antigen (TPA)

26. Biochemical Tumor Markers

ADA

BProtein

PNP

5'Nucleotidase

27. Oncogenes

Abl/ablbcr

AIB1

APC

BTA 26

BCL2

BCRABL

Braf

BRCA

CD44

CDK

Cabl

Cfos

Cmyb

Cmyc

CYCD1

CYP17

DPC

Emyc

ErbB

HER2/neu

HPC1

HSTF

Lmyc

MET

MSH

NEU

Nmyc

Ntelopeptide

PCA3

PIK3CA

PTI1

P10

P40

P51

P53

Ras

Reg

RET

sFas

Sis

Src

28. Polypeptide Growth Factors

Basic Fibroblast Growth Factor

BetaTGF

Cachectin (TNT)

Calmodulin

ECFR

Nerve Growth Factor (NGF)

Epidermal Growth Factor (EGF)

Ornithine Decarboxylase

Transferrin

Transforming Growth FactorAlpha

29. Ectopic Hormones

30. Colony Stimulating Factors

31. Lymphokines

AlphaInterferon

B Cell Growth Factors

B Cell Growth Factor (BCGF)

GammaInterferon

Interleukin1 (IL1)

Macrophage Activating Factor

32. Immunohistochemical Stains

33. Emerging Tumor Markers

NAcetylglucosamine

Actin

AlphaActin

Angiogenin

Angiostatin

Antineuronal Antibodies

7B2

B72.3

BProtein

Bax

BCDF9

BLCA4

Blood Group Antigens A,B,H

BTA

CA 50

CA 724/TAG72

CA 195

CA242

CA549

Cadherin

CAM 26

CAR3

CD105

CathepsinD

Chromogranin A and B

Cluster 1 Antigen

Cluster5/5A Antigen

COX Antigen

CTA

CU18

Cyclin

DR70

DUPAN2

Endometrial Bleeding Associated Factor

Endostatin

Epithelial Membrane Antigen

FDP

Feulgen Hydrolysis

Fibronectin

FSH

(1>3)Lfucosyltransferase

GastrinReleasing Peptide (GRP)

GDCFP15

Glucagon

Glycoamines

H23

HAAH

hk3

HPA

HSP27

Human Carcinoma Antigen

ICAM

Intermediate Filaments

Cytokeratins/CK18/Cyfra 211

Desmin

Gliofibrillary Acid Protein

Neurofilaments

Vimentin

KA 93

Kallikrein

Kinases

KP16D3

LAI

Leukocyte Common Antigen

Lewis Antigens

Lysophosphatidic Acid (LPA)

Ma 695/Ma 552

MABDF3

MAG

ME1

Minactivin

MN/CA9

MSA

Mucin Cancer Antigen (MCA)

Multiple Tumor Suppressor 1

Myosin

NEA130

NMP22

Nucleolar

OA519

Opiod Peptides

Pglycoprotein

Pancreatic Oncofetal Antigen (POA)

Parathyrcoid Hormone

Placental Lactogen

PR92

Proliferative Index, Ki67

Px

RB Inactivation/Deletion

Ret

S100 Protein

SCCL 175

Selectin

Serotonin

Sialic Acid

Sialyl SSEA1/SLX

SN10

Somatostatin

TA90

TABA

Tachykinin

TAG 12

TPS

Troponin

Tubulin

VCAM

VEGF

Villen

White Blood Cell Markers

C. Instrumentation Review And

Market Needs

1. Abbott AxSYM

2. Abbott IMx

3. Anagen AN2000/AuraFlex

4. Beckman Coulter Access

5. BioChem Pharma SR1

6. bioMerieux Vidas Series

7. Biotrol Systems 7000

8. J&J Diagnostics/Amersham Amerlite

9. J&J Diagnostics Vitros ECI

10. Olympus PK Series

11. Roche Cobas Core

12. Roche Elecsys

13. Roche ES 22

14. Roche ES 33

15. Roche ES 300/300 AL

16. Siemens ACS: 180

17. Siemens ACS: Centaur

18. Siemens ELISA Processor II/III

19. Siemens Immuno 1

20. Siemens/Opus/Plus/Magnum

21. Siemens Stratus

22. Tosoh AIA Series

23. Wallac/Pharmacia Delfia

D. Current and Emerging Technologies

1. Monoclonal and Polyclonal Antibodies

2. Immunoassays

a. Technological Principle

b. Radioimmunoassay (RIA)

c. Enzyme Immunoassays (EIA)

Overview

ELISA

Immunofiltration

ParticleMembrane Capture Immunoassay

Enzyme Amplification

d. Fluorescent Immunoassays

e. Luminescence

Chemiluminescence

Bioluminescence

3. Molecular Diagnostics

a. Technology Overview

b. Amplification Methods

PCR

DAPPCR

ImmunoPCR

QCPCR

CAR

DNA

HPA

LCR

NASBA

QBR

SDA

3 SR, and others

4. Biochips/Microarrays

5. Chromosome Analysis

a. Chronic Myelogenous Leukemia (CML)

b. Acute Myeloid Leukemia (AML)

c. Acute Lymphoblastic Leukemia (ALL)

d. Malignant Lymphomas

Lymphoid Malignancies

e. Chronic Lymphocytic Leukemia (CLL)

f. Solid Cancers

g. Chromosomal Translocation and Oncogenes

6. Microcomputers and Automation

7. Artificial Intelligence

8. Flow Cytometry

9. Biosensors

E. Competing/Complementing Technologies

1. CT

2. MRI

3. NMR

4. PET

5. Photonics Spectroscopy

F. Business Environment

1. Worldwide Market Structure

2. Worldwide Market Size and Growth

G. Personal Testing

U.S.A.

A. Executive Summary

B. Business Environment

1. Health Care Expenditures

2. Cost Consciousness

3. Reimbursement

4. Industry Consolidation

5. Managed Care

a. HMO

b. PPO

6. Hospitals

7. Admissions

8. Length of Stay

9. Industry Diversification

10. Physician Demographics

11. Population Aging

a. Chronic Illness

b. Disease Incidence

c. Susceptibility to Iatrogenesis

d. Multiple Illness Cases

12. Laboratory Regulations

13. FDA Reform

C. Market Structure

1. Centralized Testing

a. Hospitals

b. Commercial/Private Laboratories

2. POT/Decentralized Testing

a. Physician Offices/Group Practices

b. Cancer Clinics

c. Other Decentralized Testing Locations

D. Market Size, Growth and Major Suppliers Sales,

Instrument Placements and Market Shares

Major Product Development Opportunities

A. Reagent Kits and Test Systems/Panels

B. Instrumentation

C. Computers, Software and Automation

D. Auxiliary Products

Design Criteria for Decentralized Testing Products

Alternative Market Penetration Strategies

A. Internal Development

B. Collaborative Arrangements

C. University Contracts

D. Distribution Strategies

1. Marketing Approaches

2. Product Complexity

3. Customer Preference

4. Established Suppliers

5. Emerging Suppliers

6. Major Types of Distributors

7. Market Segmentation Factor

Potential Market Entry Barriers and Risks

A. Market Maturity

B. Cost Containment

C. Competition

D. Technological Edge and Limitations

E. Patent Protection

F. Regulatory Constraints

G. Decentralized Testing Market Challenges

Competitive Profiles

Abbott

AdnaGen

Ambrilia Biopharma

AMDL

Beckman Coulter

Becton Dickinson

Biomedical Diagnostics

bioMerieux

BioRad

CanAG Diagnostics

CeMines

Cepheid

Correlogic Systems

Dako

Decode

Diadexus

Diagnocure

Diasorin

Eiken Chemical

Enterix

Enzo Biochem

Epigenomics

Exact Sciences

Fujirebio

GenProbe

Guided Therapeutics

Hologic

Ipsogen

J&J Diagnostics

Kreatech

Kyowa Medex

Mackay Life Sciences

Matritech

Myriad Genetics

OncoLab

Panacea Pharmaceuticals

Polartechnics

Polymedco

PreMD

Qiagen

Radient Pharmaceuticals

Roche

Scienion

Sequenom

Siemens Healthcare

Takara Bio

Targeted Diagnostics & Therapeutics

Tosoh

Veridex

Wako Pure Chemicals

Wallac

Zila

Appendixes

Appendix I: Major Companies Developing or Marketing Tumor Marker Reagents

and Instruments

Appendix II: Major Universities and Research Centers Developing Tumor Marker Detection Technologies and Applications

Appendix III: Assumed Currency Exchange Rates

List of Tables

Tumor Marker Classification

Major Companies Developing or MarketingACTH Tests

Major Companies Developing or MarketingAFP Tests

Major Companies Developing or MarketingBeta2 Microglobulin Tests

Major Companies Developing or MarketingCA 153/27.29 Tests

Major Companies Developing or MarketingCA 199 Tests

Major Companies Developing or MarketingCA 125 Tests

Major Companies Developing or MarketingCalcitonin Tests

Major Companies Developing or MarketingCEA Tests

Major Companies Developing or MarketingEstrogen Receptor Tests

Major Companies Developing or MarketingProgesterone Receptor Tests

Major Companies Developing or MarketingFerritin Tests

Major Companies Developing or MarketingGastrin Tests

Major Companies Developing or MarketingHCG Tests

Major Companies Developing or MarketingInsulin Tests

Major Companies Developing or MarketingNSE Tests

Major Companies Developing or MarketingOccult Blood Tests

Major Companies Developing or MarketingPAP Smear/HPV Tests

Major Companies Developing or MarketingPAP Tests

Major Companies Developing or MarketingPSA Tests

Major Companies Developing or MarketingLymphocyte Subclassification Tests

Biochemical Markers Potential Applications In Cancer Diagnosis

Oncogenes Potential Applications In Cancer Diagnosis

Major Companies Developing or MarketingOncogene Tests

Growth Factors Potential Applications In Cancer Diagnosis

Colony Stimulating Factors Potential Applications in Cancer Diagnosis

Lymphokines Potential Applications In Cancer Diagnosis

Immunohistochemical Stains Potential Applications in Cancer Diagnosis

Executive Summary Table: U.S., Total Tumor Marker Test Volume and Sales Forecast by Market Segment

U.S., Estimated New Cancer Cases and Deaths

U.S., Estimated Cancer Death Rates Per 100,000 Population

U.S., Laboratories Performing Tumor Marker Tests by Market Segment

U.S., Hospital Laboratories Performing Tumor Marker Tests by Bed Size

U.S., Commercial/Private Laboratories Performing Tumor Marker Tests by

Annual Test Volume

U.S., Physician Office Laboratories Performing Tumor Marker Tests by Practice Size

U.S., Total Tumor Marker Test Volume Forecast by Market Segment

U.S., All Market Segments Major Tumor Marker Test Volume Forecast

U.S., Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test

U.S., Commercial/Private Laboratories Major Tumor Marker Test Volume Forecast

U.S., Physician Offices/Group Practices Major Tumor Marker Test Volume Forecast

U.S., Cancer Clinics Major Tumor Marker Test Volume Forecast by Assay

U.S., Total Tumor Marker Sales Forecast by Market Segment

U.S., All Market Segment Major Tumor Marker Sales Forecast by Test

U.S., Hospital Laboratories Major Tumor Marker Sales Forecast by Test

U.S., Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test

U.S., Physician Offices/Group Practices Major Tumor Marker Sales Forecast by Test

U.S., Cancer Clinics Major Tumor Marker Sales Forecast by Test

U.S., ACTH Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., AFP Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Beta2 Microglobulin Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., CA 153/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., CA 199 Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., CA125 Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Cathepsin Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., CEA Test Volume and Diagnostics Sales by Market Segment

U.S., Chromogranin Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Colonspecific Antigen Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Cytokeratins Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., HCG Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Insulin Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Interferons Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Interleukins Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., NSE Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Nucleolar Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Progesterone Receptor Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., PAP Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., PSA Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., S100 Protein Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., TDT Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Thymidine Kinase Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., TPA Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Total Tumor Marker Sales By Major Supplier

U.S., AFP Testing Market Diagnostics Sales by Major Supplier

U.S., CA 125 Testing Market Diagnostics Sales by Major Supplier

U.S., CA 153/27.29 Testing Market Diagnostics Sales by Major Supplier

U.S., CEA Testing Market Diagnostics Sales by Major Supplier

U.S., Ferritin Testing Market Diagnostics Sales by Major Supplier

U.S., HCG Testing Market Diagnostics Sales by Major Supplier

U.S., Insulin Testing Market Diagnostics Sales by Major Supplier

U.S., PAP Testing Market Diagnostics Sales by Major Supplier

U.S., PSA Testing Market Diagnostics Sales by Major Supplier

U.S., Tumor Marker Testing Instrumentation Major Systems Estimated Placements and

Installed Base by Supplier and Model

To order this report:

: US Tumor Marker Testing Market

More  Market Research Report

Check our  Real Time Industry Data

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com